Resverlogix Corp.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada. Show More...
-
Website https://www.resverlogix.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 0.05 CAD
-
Last Updated 29-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-04 2011-04 2012-04 2013-04 2014-04 2015-04 2016-04 2017-04 2018-04 2019-04 TTM Earnings Per Share USD -0.67 -0.04 0.29 0.58 -0.69 0.22 0.2 -0.44 -0.42 -0.87 0.18 Dividends USD Payout Ratio % * Shares Mil 41.0 52.0 65.0 74.0 79.0 85.0 101.0 105.0 138.0 188.0 216.0 Book Value Per Share * CAD 0.16 0.04 -0.27 -0.86 -0.77 -0.56 -1.17 -0.57 -1.05 -0.5 Free Cash Flow Per Share * CAD -0.4 -0.37 -0.37 -0.27 -0.15 -0.26 -0.31 -0.27 -0.32 Return on Assets % -200.93 -262.41 -180.62 263.82 -468.53 151.54 64.37 181.34 -609.14 366.4 Financial Leverage (Average) 1.89 1.96 4.51 Return on Equity % -341.8 -504.87 -533.52 Return on Invested Capital % -331.08 -506.27 -535.04 Interest Coverage -18.42 -10.5 -31.83 15.83 Current Ratio 1.6 1.55 1.08 0.82 0.2 0.83 2.49 0.08 0.11 0.12 0.15 Quick Ratio 1.28 1.27 0.83 0.75 0.13 0.81 2.32 0.02 0.010 0.1 0.04 Debt/Equity